IAM
CRL icon

Iridian Asset Management’s Charles River Laboratories CRL Stock Holding History

Iridian Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.7M Sell
9,845
-16,723
-63% -$3.1M 0.69% 32
2025
Q4 		$5.3M Sell
26,568
-2,058
-7% -$373K 1.95% 18
2025
Q3 		$4.48M Sell
28,626
-18,940
-40% -$3.01M 1.76% 20
2025
Q2 		$7.22M Sell
47,566
-12,853
-21% -$1.71M 2.5% 13
2025
Q1 		$9.09M Buy
60,419
+9,454
+19% +$1.59M 2.85% 12
2024
Q4 		$9.41M Sell
50,965
-4,078
-7% -$786K 2.5% 14
2024
Q3 		$10.8M Buy
55,043
+8,876
+19% +$1.84M 2.32% 17
2024
Q2 		$9.54M Buy
46,167
+21,763
+89% +$4.93M 2.15% 17
2024
Q1 		$6.61M Sell
24,404
-6,738
-22% -$1.61M 1.3% 19
2023
Q4 		$7.36M Buy
31,142
+1,803
+6% +$355K 1.34% 15
2023
Q3 		$5.75M Sell
29,339
-38,039
-56% -$7.81M 1.16% 22
2023
Q2 		$14.2M Buy
67,378
+1,309
+2% +$260K 1.32% 22
2023
Q1 		$13.3M Sell
66,069
-12,607
-16% -$2.86M 1.09% 24
2022
Q4 		$17.1M Sell
78,676
-9,288
-11% -$2.03M 1.65% 21
2022
Q3 		$17.3M Sell
87,964
-4,771
-5% -$1.03M 1.72% 24
2022
Q2 		$19.8M Buy
92,735
+18,245
+24% +$4.46M 1.62% 25
2022
Q1 		$21.2M Buy
74,490
+15,974
+27% +$4.93M 1.47% 28
2021
Q4 		$22M Sell
58,516
-52,277
-47% -$20.3M 1.35% 34
2021
Q3 		$45.7M Sell
110,793
-95,394
-46% -$39.6M 1.4% 33
2021
Q2 		$76.3M Sell
206,187
-34,754
-14% -$11.6M 1.33% 39
2021
Q1 		$69.8M Sell
240,941
-39,566
-14% -$11M 1.19% 37
2020
Q4 		$70.1M Sell
280,507
-42,648
-13% -$10.2M 1.28% 35
2020
Q3 		$73.2M Sell
323,155
-113,625
-26% -$23.6M 1.6% 32
2020
Q2 		$76.2M Sell
436,780
-40,377
-8% -$6.44M 1.68% 30
2020
Q1 		$60.2M Buy
477,157
+266,270
+126% +$39.9M 1.46% 30
2019
Q4 		$32.2M Buy
+210,887
New +$29.2M 0.53% 46

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Iridian Asset Management's CRL Position: Q1 2026 in Review

Iridian Asset Management reduced its Charles River Laboratories (CRL) stake by 63% in Q1 2026, selling an estimated $3.1M and leaving 9,845 shares worth $1.7M. The position accounts for 0.69% of the portfolio, ranked #32.

Iridian Asset Management first reported a position in CRL in Q4 2019 and has held it in 26 quarters since. The position peaked at $76.3M in Q2 2021. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Iridian Asset Management held 9,845 shares of Charles River Laboratories worth $1.7M as of Q1 2026.
  • Iridian Asset Management sold 16,723 Charles River Laboratories shares in Q1 2026, an estimated $3.1M.
  • Charles River Laboratories made up 0.69% of Iridian Asset Management's portfolio in Q1 2026, its #32 holding.
  • Iridian Asset Management first reported a position in Charles River Laboratories in Q4 2019 and has held it in 26 quarters since.
  • Iridian Asset Management's Charles River Laboratories position peaked at $76.3M in Q2 2021.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Iridian Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.